(Photo credits: Pixabay – fernando zhiminaicela)
(AOF) – OSE Immunotherapeutics announces the publication of positive phase 3 results of its vaccine in patients with lung cancer resistant to immunotherapy in the peer-reviewed journal “Annals of Oncology”. Tedopi improves overall survival with better tolerance and better quality of life as monotherapy versus chemotherapy, in HLA-A2 positive patients with advanced or metastatic NSCLC (non-small cell lung cancer) who have progressed after at least 12 weeks after sequential treatment with chemotherapy and IPC.
Nicolas Poirier, CEO of OSE Immunotherapeutics, comments: “Tedopi is the most advanced therapeutic cancer vaccine in clinical development. Our phase 3 data showing promising effects are now validated in a renowned international journal, ‘Annals of Oncology’, which represents a major breakthrough for everyone involved in the study.”
AOF – LEARN MORE
Find out more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.